Journal of the Endocrine Society · 2026
Gemcitabine and oxaliplatin combination in patients with advanced adrenocortical carcinoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Lily, Balderrama-Brondani Vania, Marcal Leonardo P, Jimenez Camilo, Varghese Jeena, Shah Amishi Y, Habra Mouhammed Amir, Campbell Matthew T
Аннотация
CONTEXT: Adrenocortical carcinoma (ACC) is a rare, aggressive malignancy with limited treatment options beyond first-line therapy, underscoring the need for effective salvage regimens.
OBJECTIVE: To evaluate the clinical activity and safety of gemcitabine and oxaliplatin (GemOx) in advanced ACC.
DESIGN: Retrospective cohort study conducted from April 2023 to April 2024 with longitudinal follow-up.
SETTING: Single-center tertiary referral cancer center.
PATIENTS OR OTHER PARTICIPANTS: Fourteen patients with histologically confirmed advanced ACC treated with GemOx were included. Patients were heavily pretreated, with a median of 3 prior systemic therapies (range, 2-9); 43% had hormonally functional tumors.
INTERVENTIONS: Gemcitabine (1000 mg/m2 on days 1 and 8) and oxaliplatin (130 mg/m2 on day 1) every 3 weeks until disease progression or unacceptable toxicity.
MAIN OUTCOME MEASURES: Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included objective response rate per Response Evaluation Criteria In Solid Tumors 1.1 and treatment-related toxic effects.
RESULTS: After a median follow-up of 10.7 months (95% CI, 8.5-15.7), median PFS was 3.2 months (95% CI, 0.4-6.0) and OS was 13.0 months (95% CI, 3.6-22.5). Among 13 evaluable patients, 2 (15.4%) achieved partial response, 8 (61.5%) had stable disease, and 3 (23.1%) had progressive disease, yielding a disease control rate of 76.9%. No treatment-related deaths occurred.
CONCLUSION: GemOx demonstrated modest clinical activity with manageable safety in heavily pretreated patients with advanced ACC. These findings suggest a potential role for GemOx as a salvage option, though validation in larger prospective studies is needed.
OBJECTIVE: To evaluate the clinical activity and safety of gemcitabine and oxaliplatin (GemOx) in advanced ACC.
DESIGN: Retrospective cohort study conducted from April 2023 to April 2024 with longitudinal follow-up.
SETTING: Single-center tertiary referral cancer center.
PATIENTS OR OTHER PARTICIPANTS: Fourteen patients with histologically confirmed advanced ACC treated with GemOx were included. Patients were heavily pretreated, with a median of 3 prior systemic therapies (range, 2-9); 43% had hormonally functional tumors.
INTERVENTIONS: Gemcitabine (1000 mg/m2 on days 1 and 8) and oxaliplatin (130 mg/m2 on day 1) every 3 weeks until disease progression or unacceptable toxicity.
MAIN OUTCOME MEASURES: Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary outcomes included objective response rate per Response Evaluation Criteria In Solid Tumors 1.1 and treatment-related toxic effects.
RESULTS: After a median follow-up of 10.7 months (95% CI, 8.5-15.7), median PFS was 3.2 months (95% CI, 0.4-6.0) and OS was 13.0 months (95% CI, 3.6-22.5). Among 13 evaluable patients, 2 (15.4%) achieved partial response, 8 (61.5%) had stable disease, and 3 (23.1%) had progressive disease, yielding a disease control rate of 76.9%. No treatment-related deaths occurred.
CONCLUSION: GemOx demonstrated modest clinical activity with manageable safety in heavily pretreated patients with advanced ACC. These findings suggest a potential role for GemOx as a salvage option, though validation in larger prospective studies is needed.